Getinge overview

1. Getinge overview An expanding Medical-Technology group with focus on comprehensive solutions for infection control, surgical systems and care of elderly and disabled people Customers Acute care Long term care Industry / Laboratories Net Sales 8.6 billion SEK Associates 5 600 Manufacturing 18 production units in 9 countries Distribution 70 sales companies in 25 countries Distributors in 100 countries (ex Jostra and LSS)

2. B u s i n e s s A r e a s Infection Control40% Extended Care31 % Surgical Systems 29 % Industry I0 % Acute Care 60 % Long Term Care 30 % C u s t o m e r S e g m e n t s (ex Jostra and LSS) Business Scope

3. Group objectives & focus

4. Getinge Group Objectives • Strategic • To develop world leading positions in prioritized • niches of the health care industry

5. Strong Global Positions Business unit Position Market shares BA Infection Control Sterilization # 1 24 % Disinfection # 1 27 % BA Surgical Systems Surgical Tables # 1 40 % Surgical Lights # 1 38 % Ventilators # 1 28 % Cardiopulmonary # 3 22 % Ceiling Service Units # 3 15 % Anaesthesia # 3 6 % BA Extended Care Hygiene Systems # 1 60 % Patient Handling # 1 40 % Wound Care # 4 5 %

6. Getinge Group Objectives • Strategic • To develop world leading positions in prioritized • niches of the health care industry • Financial • To increase profit before tax with an average of I5% • per annum • Internally generated cash flow to sustain an external • growth rate of I0% per annum

7. The Getinge Group 10000 1000 9000 8000 800 7000 6000 600 5000 4000 400 3000 2000 200 1000 CAGR 24 % 0 0 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 Invoiced sales Profit before tax

8. The Getinge Group - Focus & Development Infection Control Improved Operating Performance ExtendedCare Organic Growth SurgicalSystems External Growth

9. Review of Business Areas

10. Infection Control Create a customer focused group from a number of companies acquired over the last 10 years

11. 1990 - 2000 2000 - 2002 2003  Growth through acquisition Business development Restructuring - Improve production structure- Organisational focus - Brand identity - Organic growth- Product development - Integrated solutions - Logistics / distribution - Service provider concept INFECTION CONTROL

12. Infection ControlOrders received MSEK

13. Infection ControlResults MSEK

14. Extended Care Focus on growth from a solid platform through product innovation, market penetration and geographical expansion

15. HIGHLIGHTS 2003 GROWTH • Market penetration • Strong product pipeline • Geographical expansion COMPETITIVENESS • Global sourcing • Improved productionstructure • Improved logistics

16. Extended CareOrders received MSEK

17. Extended CareResultsMSEK

18. Surgical Systems Create a global leader in the field of Surgical workstations as a platform for further growth in the surgical systems market

19. SURGICAL WORKSTATIONS • Growth opportunities • Japan and USA • Product development • AWIGS / VIWAS • New Pendant generation • New Light technology • Cross selling • Heraeus integration

20. OPERATING THEATRE

21. Radiology Disposables Patient monitoring Surgical instruments Life Support Ancillary Equipment EXTERNAL GROWTH Surgical Systems

22. Acquisition of Jostra - business unit Cardiopulmonary

23. Jostra in brief • Sales approx 90 M EUR in 2002 • Associates ~ 600 • Sales in 100 countries, own sales companies in: • DE, FR, IT, JP, CA, ES, GB, NL, SE, CN, HK • Production: Germany (2 sites), Sweden and Denmark • Products: Heart-lung machines, Oxygenators, Centrifugal pumps, related Disposables, Minimal Invasive on-pump Equipment • Excellent technology and product pipeline, 55 issued patents • Good track record of organic growth 10% +

24. Jostra Integration and Restructuring • New management team from 1st August 2003 • Integration of Jostra’s sales and marketing • organisation with that of Surgical Systems • Consolidation of Jostra production structure from 4 to • 2 sites • Reinforce sales and marketing organisation to drive • market penetration in Europe and emerging markets • Focus the R&D pipeline to deliver new technologies in • a speedy and timely manner

25. Jostra Acquisition Financials • The target is to improve Jostra’s EBIT margin to • 12 - 15% within 3 years after goodwill amortization • Contribution to group earnings in 2003 will be • slightly negative to neutral • Contribution to group pre-tax profit including • goodwill amortization and related financial charges • will be in the range of EUR 5 - 6 million in 2004

26. Acquisition of Siemens LSS - business unit Critical Care

27. Sales of 175 MEUR Global marketshares 27% Sales of 30 MEUR Global marketshares 6% Key Data of LSS Life Support Systems (LSS) LSS is one of the world’s leading providers of ventilation and anaesthesia products in the critical care equipment market In 2002/03, LSS have projected revenues of around 205 MEUR The worldwide ventilation and anaesthesia hospital markets account for approx 550 MEUR annual sales volume each, with an expected annual growth of approx. 5% p.a. LSS-Ventilation LSS-Anaesthesia

28. Total LSS Sales in 2002 by Region

29. Financials LSS will contribute with 10 - 12 MEUR to pretax profit in fiscal 2004 LSS will contribute with 17 - 20 MEUR to pretax profit in fiscal 2005 Operating margins after goodwill depreciation is targeted at 15% longterm

30. Surgical SystemsOrders received MSEK

31. Surgical SystemsResultsMSEK

32. Results Q3 2003

33. Getinge ABResults MSEK

34. Getinge ABBalance sheets MSEK

35. Getinge ABKey figures